OTC Markets OTCQB - Delayed Quote USD

MediPharm Labs Corp. (MEDIF)

0.0610

-0.0005

(-0.81%)

At close: April 17 at 3:34:10 PM EDT

MediPharm Labs Reports Full Year & Fourth Quarter 2024 Results

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the full year and three months ended December 31, 2024.

CNW Group 19 days ago

MEDIF
-0.81%
MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2024 Financial Results

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its full year and fourth quarter financial results for the three and twelve months ended December 31st, 2024, before markets open on Monday, March 31st, 2025.

PR Newswire 24 days ago

MEDIF
-0.81%
AKITA Drilling And 2 Other Promising Penny Stocks On The TSX

The Canadian market has been navigating a landscape of uncertainty, with recent tariff threats and political ambiguities influencing investor sentiment. Amidst these challenges, investors often look for opportunities that balance affordability with growth potential. Penny stocks, despite their somewhat outdated name, continue to offer intriguing possibilities for those seeking hidden value in smaller or newer companies. These stocks can present significant upside when backed by strong...

Simply Wall St. last month

AKTAF

MEDIF
-0.81%
GKPRF
Promising TSX Penny Stocks To Consider In February 2025

The Canadian market is navigating a complex landscape, with tariffs posing potential risks to economic growth and inflation. Despite these challenges, opportunities for investors remain, particularly in the realm of penny stocks. While the term may seem outdated, these smaller or newer companies can offer significant growth potential when backed by strong financials and sound fundamentals.

Simply Wall St. 2 months ago

CHPGF

MEDIF
-0.81%
NFGC
MediPharm Labs Announces Termination of the Proposed Sale of Napanee Facility to Kensana Health

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) ("MediPharm", "MediPharm Labs" or the "Company") has terminated the previously announced sale of its facility in Napanee, Ontario (the "Napanee Facility") to Kensana Health Inc. ("Kensana Health"), which was to be completed through the sale of the Company's wholly-owned subsidiary ABcann Medicinals Inc. ("ABcann") to Kensana Health pursuant to the terms of a share purchase agreement (as amended, the "Purchase Agreement") entered into with Kensana H

PR Newswire 2 months ago

MEDIF
-0.81%
MediPharm Labs Provides Update on Previously Announced Sale of Napanee Facility to Kensana Health

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) ("MediPharm", "MediPharm Labs" or the "Company") is pleased to provide an update with respect to the previously announced sale of its facility in Napanee, Ontario (the "Napanee Facility") to be completed pursuant to the terms of a share purchase agreement (the "Purchase Agreement") entered into with Kensana Health Inc. ("Kensana Health") through a disposition of all of the Company's indirect equity interests in its wholly-owned subsidiary ABcann Me

CNW Group 3 months ago

MEDIF
-0.81%
MediPharm Labs Enters Landmark Commercial Agreement with Laboratório Teuto in Brazil

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) ("MediPharm" or the "Company"), a leader in pharmaceutical-grade cannabis manufacturing, is proud to announce a commercial agreement with Laboratório Teuto ("Teuto"), a leading pharmaceutical manufacturer and marketer in Brazil. This partnership signifies a significant milestone as MediPharm expands its reach into one of the most tightly regulated medical cannabis markets globally.

CNW Group 3 months ago

MEDIF
-0.81%
TSX Penny Stocks With Market Caps Over CA$20M To Consider

The Canadian market has recently experienced a pullback, with the TSX index losing about 6.5% since its peak in December, reflecting uncertainties in political leadership and policy shifts. Despite these challenges, the underlying economic growth and easing inflation present opportunities for investors willing to navigate this volatility. For those interested in smaller or newer companies, penny stocks—though an older term—remain a relevant investment area; when backed by strong financials,...

Simply Wall St. 3 months ago

MEDIF
-0.81%
BCBNF

MGAFF
MediPharm Labs to Sell its Napanee Facility to Kensana Health for $5.5M

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) ("MediPharm", "MediPharm Labs" or the "Company") and Kensana Health Inc. ("Kensana Health") are pleased to announce that they have entered into a share purchase agreement (the "Purchase Agreement") for the purchase and sale of MediPharm's facility in Napanee, Ontario (the "Napanee Facility") through a disposition of all of the Company's indirect equity interests in its wholly-owned subsidiary ABcann Medicinals Inc. ("ABcann") to Kensana Health for

CNW Group 3 months ago

MEDIF
-0.81%
MediPharm Labs Reports Third Quarter Results

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids announced its financial results for the three and nine months ended September 30, 2024.

PR Newswire 5 months ago

MEDIF
-0.81%
3 TSX Penny Stocks With Market Caps Under CA$30M To Consider

The Canadian market, like its U.S. counterpart, has been experiencing a notable upswing following the recent decisive election outcome in the United States, which has cleared a significant source of uncertainty for investors. Amid this backdrop of shifting political landscapes and economic fundamentals, penny stocks continue to capture interest as potential investment opportunities due to their affordability and growth potential. While the term "penny stocks" may seem outdated, these...

Simply Wall St. 5 months ago

MEDIF
-0.81%
WPNDF

BTLLF
MediPharm Labs Sets Date to Report Third Quarter 2024 Financial Results

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its third quarter financial results for the three and nine months ended September 30, 2024, before markets open on Thursday, November 14, 2024.

CNW Group 5 months ago

MEDIF
-0.81%
MediPharm Labs Announces Departure of President and Co-Founder Keith Strachan

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) ("MediPharm", "MediPharm Labs" or the "Company"), a specialized, research-driven company focused on pharmaceutical-quality cannabis extraction and cannabis based health products, is announcing that President and Co-Founder Keith Strachan will be stepping down from his management position effective December 31, 2024. Keith will continue to provide strategic support and guidance to the Company by joining the Board of Directors effective January 1, 20

CNW Group 5 months ago

MEDIF
-0.81%
MediPharm Labs Announces $2.1M Debt Repayment

MediPharm Labs Corp. ("MediPharm" or the "Company") (TSX: LABS), a specialized, research-driven pharmaceutical company focused on cannabis-based health products, is pleased to announce that it has paid off the entire remaining convertible debt amount of $2.1 million, leaving the Company materially debt-free.

CNW Group 6 months ago

MEDIF
-0.81%
MediPharm Labs Reports Second Quarter Results Closing in on Positive Adjusted EBITDA(1) as Gross Profit Continues to Improve

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids announced its financial results for the three and six months ended June 30, 2024 ("Q2 2024").

PR Newswire 8 months ago

MEDIF
-0.81%
/R E P E A T -- MediPharm Labs Sets Date to Report Second Quarter 2024 Financial Results/

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its second quarter financial results for the period ended June 30, 2024, before markets open on Wednesday, August 14, 2024.

CNW Group 8 months ago

MEDIF
-0.81%
MediPharm Labs Announces Voting Results From the 2024 Annual Meeting of Shareholders

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today announced the results of matters voted on at its annual meeting of holders of common shares ("Shareholders") held on Wednesday, June 26, 2024 (the "Meeting"). The voting results for each of the matters presented at the Meeting are outlined below.

PR Newswire 9 months ago

MEDIF
-0.81%
MediPharm Labs Acquires Advanced Medical Cannabis Delivery Method Technology from Remidose Aerosols

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has entered into a licencing agreement with Remidose Aerosols Inc. ("Remidose") to acquire the exclusive rights for advanced cannabis products (the "Agreement").

CNW Group 9 months ago

MEDIF
-0.81%
MediPharm Labs Reports First Quarter Results

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids announced its financial results for the three months ended March 31, 2024.

CNW Group 10 months ago

MEDIF
-0.81%
MediPharm Labs Sets Date to Report First Quarter 2024 Financial Results

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its first quarter financial results for the period ended March 31, 2024, before markets open on Wednesday, May 15, 2024.

PR Newswire 11 months ago

MEDIF
-0.81%

Performance Overview

Return	MEDIF	S&P/TSX Composite index (^GSPTSE)
YTD	+38.64%	-1.74%
1-Year	+5.17%	+11.71%
3-Year	-42.99%	+10.69%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

MediPharm Labs Corp. (MEDIF)

MediPharm Labs Reports Full Year & Fourth Quarter 2024 Results

MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2024 Financial Results

AKITA Drilling And 2 Other Promising Penny Stocks On The TSX

Promising TSX Penny Stocks To Consider In February 2025

MediPharm Labs Announces Termination of the Proposed Sale of Napanee Facility to Kensana Health

MediPharm Labs Provides Update on Previously Announced Sale of Napanee Facility to Kensana Health

MediPharm Labs Enters Landmark Commercial Agreement with Laboratório Teuto in Brazil

TSX Penny Stocks With Market Caps Over CA$20M To Consider

MediPharm Labs to Sell its Napanee Facility to Kensana Health for $5.5M

MediPharm Labs Reports Third Quarter Results

3 TSX Penny Stocks With Market Caps Under CA$30M To Consider

MediPharm Labs Sets Date to Report Third Quarter 2024 Financial Results

MediPharm Labs Announces Departure of President and Co-Founder Keith Strachan

MediPharm Labs Announces $2.1M Debt Repayment

MediPharm Labs Reports Second Quarter Results Closing in on Positive Adjusted EBITDA(1) as Gross Profit Continues to Improve

/R E P E A T -- MediPharm Labs Sets Date to Report Second Quarter 2024 Financial Results/

MediPharm Labs Announces Voting Results From the 2024 Annual Meeting of Shareholders

MediPharm Labs Acquires Advanced Medical Cannabis Delivery Method Technology from Remidose Aerosols

MediPharm Labs Reports First Quarter Results

MediPharm Labs Sets Date to Report First Quarter 2024 Financial Results

Performance Overview